OncoMed Pharmaceuticals, Inc. Initiates Second Phase 1b Clinical Trial For OMP-54F28 (Fzd8-Fc) With Sorafenib (Nexavar®) In Hepatocellular Cancer

REDWOOD CITY, Calif., Feb. 18, 2014 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced that it has started a multi-center Phase 1b clinical trial of OMP-54F28 (Fzd8-Fc) with sorafenib (Nexavar®) in hepatocellular cancer (HCC). OMP-54F28 is a first-in-class Wnt-pathway-targeting decoy receptor and is part of OncoMed's collaboration with Bayer Pharma AG (Bayer). This is the second of three Phase 1b trials for OMP-54F28 to begin patient enrollment; earlier this year OncoMed initiated a Phase 1b of OMP-54F28 with nab-paclitaxel (Abraxane®) and gemcitabine in pancreatic cancer.

Help employers find you! Check out all the jobs and post your resume.